News
Celon Pharma S.A. Partners for the Commercialization of Reduzek (generics semaglutide) in the Gulf Cooperation Council (GCC) Countries
Celon Pharma S.A. has entered into a License and Supply Agreement with Pharmalink Drug Store L.L.C. for the commercialization of Celon Pharma’s generic semaglutide products in selected markets of the Gulf Cooperation Council (GCC) countries. The partnership represents another step in the Company’s strategy to build an international commercial presence for its GLP-1 analogue portfolio.Read more »
Representatives of the European Bank for Reconstruction and Development and Celon Pharma met to discuss the progress of the Reduzek project
This is strategic investment related to the development and production of GLP-1 semaglutide, used in the treatment of type II diabetes and obesity. During the meeting, the parties reviewed the current status of the project, the investment implementation schedule, and the financial cooperation concerning the construction and launch of the Celon Pharma Slovakia manufacturing facilityRead more »
Diamonds of Innovation 2025 for Celon Pharma
Celon Pharma has been named a laureate of the prestigious Diamonds of Innovation 2025 competition in the Pharmacy and Biotechnology category. The award was received by Krzysztof Dubiel, Director of Medicinal Chemistry at Celon Pharma, during the Executive Innovation Forum 2025 gala – an event that annually brings together leaders of innovation, business, and science.Read more »
Current Report No. 8/2025 – Execution of agreement on support for a Celon Pharma S.A. project under the National Recovery and Resilience Plan
Subject: Execution of agreement on support for a Celon Pharma S.A. project under the National Recovery and Resilience PlanLegal basis: Article 17(1) of Regulation (EU) No. 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (Market Abuse Regulation – MAR) – inside informationDate and time of disclosure: 6Read more »
CPL’36 Phase II clinical results to be presented at APA Annual Meeting
We’re excited to share that we’ll be presenting at the American Psychiatric Association (APA) Annual Meeting 2025, taking place May 17–21 in Los Angeles, California. Our team will showcase the Phase 2 clinical trial results of CPL’36, an innovative PDE10A inhibitor, in the treatment of acute exacerbations of schizophrenia. 📌 Poster session: May 18, 1:30–3:00Read more »
Current report 4/2025 – Phase II top – line results for CPL’ 36, a PDE10a inhibitor in the treatment of Dyskinesia in Parkinson’s disease
Legal basis Art. 17 section 1 MAR – confidential information. Report content: In reference to current report 17/2024 regarding positive results of the Phase II clinical trial on a drug based on CPL’36, an innovative PDE10A inhibitor, in the treatment of schizophrenia, in which the Company informed about the simultaneous ongoing Phase II clinical trialRead more »
Current report no. 11/2022 – Positive outcome of FDA’s assessment process of the IND application concerning the commencement of a clinical trial for Falkieri (Celon’s esketamine DPI)
In connection with current report No. 9/2022 of 20 April 2022 on Celon Pharma S.A. (the “Company”) submitting an application to the Food and Drug Administration (FDA), the Management Board of the Company informs that today it has received information from the American regulatory authority that the Company may commence clinical trials of Falkieri (Celon’sRead more »
Celon Pharma at the #BIO2022 Convention
On 13-16 June this year, representatives of Celon Pharma will take part in this year’s BIO International Convention. This is the world’s largest meeting of representatives of the life industry, returning after the pandemic break in the classic formula. The participation of the company’s representatives is an expression of celon Pharma’s consistently implemented strategy ofRead more »
Celon Pharma joined the beneficiaries of the international project ORBIS – Open Research Biopharmaceutical Internships Support
The overall objective of the ORBIS project is to improve the development of innovative and generic medicines. The way to achieve this goal is the cooperation of representatives of academic institutions from various fields of pharmaceutical sciences and the research and development sector of companies. Therefore, the core of the project is the international exchangeRead more »